Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin plus ticagrelor versus aspirin plus clopidogrel after PCI for coronary bifurcation lesions
ChiCTR1900025059Phase 4Not yet recruiting
- Sponsor
- Army Medical University
- Start
- Sep 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of aspirin, ticagrelor and clopidogrel in coronary arteriosclerosis (2 arms), sponsored by Army Medical University. Primary endpoint: major adverse cardiovascular event. Planned start Sep 2019; status: not yet recruiting.
02
Drugs
aspirinticagrelorclopidogrel
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR1900025059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025059.